You can buy or sell Provention Bio and other stocks, options, ETFs, and crypto commission-free!
Provention Bio, Inc. Common Stock, also called Provention Bio, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Read More Its products include PRV-031 for the interception of type 1 diabetes (T1D); PRV-015 for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 for Crohn's disease; PRV-300 for ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of T1D onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ.
Lebanon, New Jersey
52 Week High
52 Week Low
Markets InsiderMay 8
Provention Bio Announces Top-Line Results from its Phase 1b PULSE Clinical Trial of PRV-300 in Patients with Moderate-to-Severe Ulcerative Colitis
OLDWICK, N.J., May 8, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced preliminary top-line results from its Phase 1b PULSE study which evaluated PRV-300, an anti-TLR3 (toll-like receptor 3) monoclonal antibody, in patients with active, moderate-to-severe ulcerative colitis (UC). PRV-300 met the primary safety and tolerability endpoint over the twelve-week study period and ...
Expected Aug 13, After Hours